Belarif, Lyssia
Mary, Caroline
Jacquemont, Lola
Mai, Hoa Le
Danger, Richard
Hervouet, Jeremy
Minault, David
Thepenier, Virginie
Nerrière-Daguin, Veronique
Nguyen, Elisabeth
Pengam, Sabrina
Largy, Eric
Delobel, Arnaud
Martinet, Bernard
Le Bas-Bernardet, Stéphanie
Brouard, Sophie
Soulillou, Jean-Paul
Degauque, Nicolas http://orcid.org/0000-0003-2990-3513
Blancho, Gilles
Vanhove, Bernard
Poirier, Nicolas
Article History
Received: 6 December 2017
Accepted: 26 September 2018
First Online: 26 October 2018
Competing interests
: The authors of this manuscript have conflicts of interest to disclose: CM, JPS, SB, BV and NP are shareholders of OSE Immunotherapeutics, a company owning patented anti-IL-7 receptor antagonists in clinical development. The remaining authors declare no competing interests.